RxDoctor Payments Data

Jeffrey Golden, MD

Family Medicine · Somerset, KYNPI 1083688444

Payments from drug & device makers

$717in general payments, 2019–2025

Across 32 payments — averaging $22.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$149
  • AbbVie$137
  • Intuitive Surgical$73
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$61
  • Novartis$48
  • Xeris Pharmaceuticals, Inc.$46
  • plus $203 from 8 others

What the payments were for

  • Food & beverage$717100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$717 in reported general payments places this provider in the 50th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$8,868
Medicare patients
37
Services billed
127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide114$138,308
EliquisApixaban108$98,486
JardianceEmpagliflozin67$60,311
TrulicityDulaglutide58$54,883
MounjaroTirzepatide42$54,364
FarxigaDapagliflozin Propanediol50$53,845
XareltoRivaroxaban45$45,855
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr57$29,412
JanuviaSitagliptin Phosphate29$23,519
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$17,644
Spiriva HandihalerTiotropium Bromide16$16,833
EntrestoSacubitril/Valsartan11$14,744
BrilintaTicagrelor18$14,728
VascepaIcosapent Ethyl21$13,710
Lantus SolostarInsulin Glargine,hum.Rec.Anlog55$8,366

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$37$138,308114 claims
Lilly USA, LLCTrulicity, Mounjaro$28$109,246100 claims
PfizerEliquis, Prempro$13$101,340120 claims
Johnson & JohnsonXarelto$29$45,85545 claims
NovartisEntresto$48$14,74411 claims
AbbVieLinzess, Synthroid$137$8,91953 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Somerset

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →